CN1652813A - 包含甘露糖结合凝集素的药用组合物 - Google Patents

包含甘露糖结合凝集素的药用组合物 Download PDF

Info

Publication number
CN1652813A
CN1652813A CNA038105802A CN03810580A CN1652813A CN 1652813 A CN1652813 A CN 1652813A CN A038105802 A CNA038105802 A CN A038105802A CN 03810580 A CN03810580 A CN 03810580A CN 1652813 A CN1652813 A CN 1652813A
Authority
CN
China
Prior art keywords
mbl
composition according
composition
gly
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038105802A
Other languages
English (en)
Chinese (zh)
Inventor
杰斯珀·L·拉森
利夫·康格斯利夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NatImmune AS
Original Assignee
NatImmune AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NatImmune AS filed Critical NatImmune AS
Publication of CN1652813A publication Critical patent/CN1652813A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CNA038105802A 2002-03-15 2003-03-14 包含甘露糖结合凝集素的药用组合物 Pending CN1652813A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200200414 2002-03-15
DKPA200200414 2002-03-15

Publications (1)

Publication Number Publication Date
CN1652813A true CN1652813A (zh) 2005-08-10

Family

ID=27763313

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038105802A Pending CN1652813A (zh) 2002-03-15 2003-03-14 包含甘露糖结合凝集素的药用组合物

Country Status (11)

Country Link
US (1) US7462596B2 (enExample)
EP (1) EP1344533B1 (enExample)
JP (1) JP2005526084A (enExample)
CN (1) CN1652813A (enExample)
AT (1) ATE337014T1 (enExample)
AU (1) AU2003215524A1 (enExample)
DE (1) DE60307701T2 (enExample)
DK (1) DK1344533T3 (enExample)
ES (1) ES2271515T3 (enExample)
PT (1) PT1344533E (enExample)
WO (1) WO2003077937A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030119734A1 (en) 2001-06-28 2003-06-26 Flink James M. Stable formulation of modified GLP-1
GB0222014D0 (en) * 2002-09-23 2002-10-30 Leuven K U Res & Dev Mannan-binding lectin
WO2004105790A1 (en) 2003-06-03 2004-12-09 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
JP4936884B2 (ja) 2003-06-03 2012-05-23 ノボ・ノルデイスク・エー／エス 安定化された薬学的ペプチド組成物
PT1687019T (pt) 2003-11-20 2018-02-26 Novo Nordisk As Formulações de péptidos que contêm polietileno glicol que são ótimas para produção e para utilização em dispositivos de injeção
US7335633B2 (en) * 2004-01-12 2008-02-26 Cornell Research Foundation, Inc. Detecting recurrent vulvovaginal candidiasis or vulvar vestibulitis syndrome and method for treating same
EP1618887A1 (en) * 2004-07-12 2006-01-25 UMC Utrecht Holding B.V. Clearance of polyols from the body
EP1789434B1 (en) 2004-08-31 2013-11-20 Novo Nordisk A/S Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins
EP2494983B1 (en) 2004-11-12 2019-04-24 Novo Nordisk A/S Stable formulations of glp-1
CN101094651B (zh) * 2004-12-30 2011-03-09 多贝尔有限公司 含有胶原凝集素家族蛋白质或者其变体的喷雾干燥的组合物和其制备方法
JP2008535872A (ja) * 2005-04-11 2008-09-04 ナットイムネ・アクティーゼルスカブ 免疫障害を持つ個体の処置におけるマンナン結合レクチン（ｍｂｌ）の新規癌適用
TW200727900A (en) * 2005-07-27 2007-08-01 Yakult Honsha Kk Aqueous solution preparation containing camptothecins
WO2007102736A2 (en) * 2006-03-08 2007-09-13 Universitair Medisch Centrum Utrecht Interfering in activation of an immune cell by influencing interaction of lair and collagen.
CN104586832B (zh) * 2007-09-10 2018-02-16 北京强新生物科技有限公司 用于癌症治疗的组合物和方法
GB0821806D0 (en) * 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
WO2011006982A2 (en) * 2009-07-17 2011-01-20 Rigshospitalet Inhibitors of complement activation
ES2678143T3 (es) 2010-01-19 2018-08-09 President And Fellows Of Harvard College Opsonina obtenida por ingeniería genética para la detección y el tratamiento de microorganismos patógenos
CN103025159A (zh) 2010-03-19 2013-04-03 波士顿生物医学公司 靶向癌症干细胞的新方法
EP2734843A2 (en) 2011-07-18 2014-05-28 President and Fellows of Harvard College Engineered microbe-targeting molecules and uses thereof
AU2013225823A1 (en) 2012-02-29 2014-09-18 President And Fellows Of Harvard College Rapid antibiotic susceptibility testing
EP2861246B1 (en) * 2012-06-18 2021-01-20 Omeros Corporation Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders
EP2976642A4 (en) 2013-03-15 2016-09-21 Harvard College METHOD AND COMPOSITIONS FOR IMPROVING THE DETECTION AND / OR RECORDING OF A TARGET UNIT
KR20150139955A (ko) 2013-04-09 2015-12-14 보스톤 바이오메디칼, 인크. 암 치료에 사용하기 위한 2-아세틸나프토[2,3-b]푸란-4,9-디온
US9988617B2 (en) 2013-05-21 2018-06-05 President And Fellows Of Harvard College Engineered heme-binding compositions and uses thereof
EP3546474B1 (en) 2013-12-18 2021-07-07 President and Fellows of Harvard College Crp capture/detection of gram positive bacteria
CN108289928B (zh) 2015-08-06 2024-09-17 哈佛大学校长及研究员协会 改进的微生物-结合分子和其用途
JP7106563B2 (ja) 2016-11-29 2022-07-26 スミトモ ファーマ オンコロジー， インコーポレイテッド ナフトフラン誘導体、その調製、および使用方法
WO2018213424A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
HUE066356T2 (hu) 2017-08-24 2024-07-28 Novo Nordisk As GLP-1 készítmények és alkalmazásaik
CN110755601B (zh) * 2019-10-31 2023-06-23 云南康洲生物科技有限公司 一种治疗hiv/aids免疫重建缺陷的芸豆凝集素植物药组合物和制备方法及其应用
PE20221575A1 (es) 2020-02-18 2022-10-06 Novo Nordisk As Formulaciones farmaceuticas
EP4408861A1 (en) * 2021-10-01 2024-08-07 Institute of Chemistry, Technology and Metallurgy Carbohydrate binding polypeptide of savalia savaglia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6429192B1 (en) * 1998-06-10 2002-08-06 Statens Serum Institut Purification process for production of mannan-binding lectin and an MBL medicinal product
AU764066B2 (en) * 1998-06-10 2003-08-07 Statens Serum Institut Purification process for production of mannan-binding lectin and an MBL medicinal product
US6297024B1 (en) * 1998-10-15 2001-10-02 Cell Activation, Inc. Methods for assessing complement activation
CA2372128A1 (en) * 1999-05-14 2000-11-23 Steffen Thiel Novel indications of mannan-binding lectin (mbl) in the treatment of immunocompromised individuals
US7211396B2 (en) * 2002-04-18 2007-05-01 Antibodyshop A/S Antibody pairs and kits for immunochemical determination of mannan-binding lectin

Also Published As

Publication number Publication date
AU2003215524A1 (en) 2003-09-29
US7462596B2 (en) 2008-12-09
JP2005526084A (ja) 2005-09-02
DK1344533T3 (da) 2007-01-08
EP1344533A1 (en) 2003-09-17
WO2003077937A1 (en) 2003-09-25
US20040006009A1 (en) 2004-01-08
DE60307701D1 (de) 2006-10-05
DE60307701T2 (de) 2007-10-11
ATE337014T1 (de) 2006-09-15
PT1344533E (pt) 2007-01-31
EP1344533B1 (en) 2006-08-23
ES2271515T3 (es) 2007-04-16

Similar Documents

Publication Publication Date Title
EP1344533B1 (en) Pharmaceutical compositions comprising mannose binding lectin
CN1359420A (zh) 重组人甘露聚糖结合型凝集素
CN105816858A (zh) 重组vwf配方
CN1636592A (zh) 稳定化的含多肽的液体药物组合物
CN1248731C (zh) 肿瘤抑制基因与化学药物在制备用于治疗肿瘤的药物组合物中的联合应用
CN1845753A (zh) 因子ⅶ多肽类的含水液体药物组合物
CN1499981A (zh) Vii因子多肽和ix因子多肽的联合应用
CN1756559A (zh) 稳定的含组织因子通路抑制剂或组织因子通路抑制剂变体的液体组合物
CN1925866A (zh) 细菌感染的治疗
CN1646152A (zh) 甘露糖结合凝集素及其应用
HK1045846A1 (zh) 低分子量补体蛋白酶抑制剂
JP2023123738A (ja) 組換えｖｗｆの投与による重度のフォンヴィレブランド病を患う患者における消化管出血の治療
CN1516591A (zh) 治疗组合物的制备
JP2025128168A (ja) 組換えＶＷＦ（ｒＶＷＦ）を使用する予防治療法
JP2025120220A (ja) クロマトグラフィー法によるｖｗｆとｖｗｆプロペプチドの分離
CN1867581A (zh) Il－21衍生物
EP4084867A1 (en) Compositions having thioredoxin activity and related methods
CN1691957A (zh) 蛋白酶抑制剂
WO2022271962A1 (en) Formulations of factor viii chimeric proteins and uses thereof
US20070218535A1 (en) Methods for production of recombinant alpha1-antitrypsin
CN1889972A (zh) 用于治疗逆转录病毒疾病的抗凝血酶ⅲ药物组合物
CN1882357A (zh) 因子xi的治疗应用
CN1805753A (zh) 重症急性呼吸综合症(sars)的治疗
CN1950103A (zh) 骨疾病的预防或治疗方法
WO2007149343A2 (en) Proteases for treatment of venomous bites

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication